Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
ARES is a multi-centre, retrospective-prospective, non-comparative and non-treatment (watch-and-measure (no experimental treatment required)) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated tezepelumab (no more than 4 weeks before inclusion) for treatment of CRSwNP (with or without comorbid asthma).
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 110 people at 10 sites. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Open-label Single-arm, Non-interventional, Multi-centre Study for Evaluation of Clinical and Patient Reported Outcomes in Adult Patients With CRSwNP on Tezepelumab
Primary outcome (registry wording): 1. Change in endoscopic status of CRSwNP based on NPS
Who it is for (from inclusion criteria)
Ages 18 Years to any
Male or female participants aged 18 years or older at the time of signing the ICF
Diagnosis of CRSwNP established for at least 52 weeks prior to tezepelumab initiation
Availability of participants' medical records for at least 52 weeks prior to tezepelumab initiation, including history of sCS use / nasal polyps surgery (or information about contraindications / intolerance to)
Prescribed and initiated treatment with tezepelumab according to SmPC and local market reimbursement criteria. A period between treatment initiation and enrolment should be no more than 4 weeks
The severity of CRSwNP consistent with need for surgery as defined by total NPS ≥ 5 (at least 2 for each nostril) at the enrollment
Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22) ≥ 3 at the enrollment
SNOT-22 total score ≥ 30 at enrollment or up to 12 weeks before enrollment
Who the registry excludes
Any contraindication to tezepelumab as per the approved product SmPC in Russia or in the opinion of the Investigator
Participation in an watch-and-measure (no experimental treatment required) study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an treatment clinical trial in the last 3 months
This study is designed to measure the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.
Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation.
Asthma is one of the most common chronic diseases. Asthma is characterized by chronic airway inflammation and associated with airway hyperresponsiveness and reversible airflow obstruction.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07399665?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07399665?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.